Aural Analytics, Inc. announced they have entered into a partnership with Medidata, enabling speech analytics as part of the Medidata Sensor Cloud Network. Aural Analytics' best-in-class speech platform Speech Vitals supports Medidata's objective of enabling the discovery and delivery of third-party algorithms at scale, leading to breakthroughs in advancing the understanding of disease progression. This will drive the development of more effective treatments for patients.

Their analytics automatically extract clinically relevant biomarkers that are meaningful, interpretable, and have a demonstrated Aural Analytics and Medidata are collaborating to deploy Speech Vitals as a standard offering within Medidata's Sensor Cloud to further the breadth of its offering to critical data streams for researchers to leverage in their studies. Speech measures have been demonstrated to have clinical relevance across cognitive, motor, respiratory, and behavioral domains and, along with other digital sensors, offer additional ways to characterize treatment effect, phenotype participants, and gain understanding of the impact of disease in a real-world setting. Aural Analytics' technology is built on decades of research and provides generalizable metrics that precisely measure the impact of neurodegenerative and neuropsychiatric conditions on speech.

These metrics are clinically validated and have demonstrated repeatability in clinical trials across 15 conditions. In addition, the ability of speech assessments to be conducted remotely reduces participant burden and achieves greater scalability.